Search clinical trials for: V930

Total 52 results

Merck Sharp & Dohme LLC

Completed

A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)

Cancer
Merck Sharp & Dohme LLC

Completed

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Melanoma | Renal Cell Carcinoma | Breast Cancer | Prostate Cancer | Bladder Carcinoma | Colon Carcinoma | Non-Small Cell Lung Carcinoma | Upper GI Tract Carcinoma
Merck Sharp & Dohme LLC

Completed

V930 First in Man (FIM) Study (V930-002)(COMPLETED)

Cancers Expressing HER-2 and/or CEA
Merck Sharp & Dohme LLC
University of California, San Diego; Inovio Pharmaceuticals

Completed

A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001)

Healthy
Merck Sharp & Dohme LLC

Completed

A Study of V950 in People With Alzheimer Disease (V950-001 AM7)

Alzheimer Disease
Merck Sharp & Dohme LLC

Completed

Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)

Prevention of Ebola Infection
Chong Kun Dang Pharmaceutical

Completed

The Pharmacokinetics of D565 and the Drug Effect of D565 on Pharmacokinetic Characteristics of D930

Healthy

Korea, Republic of
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Ocular Hypertension | Primary Open-angle Glaucoma

Korea, Republic of
Venthera, Inc., a BridgeBio company

Terminated

First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

Lymphatic Malformation | Venous Malformation | Venolymphatic Malformation

United States
Chong Kun Dang Pharmaceutical

Completed

Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930

Glaucoma

Korea, Republic of
Shire

Completed

A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.

Healthy Volunteers

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase 1 Study of OSI-930 in Cancer Patients

Advanced Solid Tumors

United States, United Kingdom
Merck Sharp & Dohme LLC
National Institute of Allergy and Infectious Diseases (NIAID); BioProtection...

Completed

Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)

Ebola Viruses
Shire

Completed

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

Hereditary Angioedema (HAE)

United States, Jordan, Italy
Celgene

Terminated

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

Fibrosis | Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Lung Diseases, Interstitial | Interstitial Lung Disease

United States, Canada
Sonova AG

Completed

Quality Control of CE-Certified Phonak Hearing Aids - 2015_03

Hearing Loss

Switzerland
Shire
Dyax Corp.

Completed

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Hereditary Angioedema (HAE)

United States, Canada, Germany, Italy, Jordan, Puerto Rico, United Kingdom
Shire

Completed

A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children (SPRING)

Hereditary Angioedema

United States, Canada, Germany, Hungary, Spain
Merck Sharp & Dohme LLC
Department of Health and Human Services; BioProtection Systems Corporation

Completed

Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)

Ebola Virus
Takeda

Completed

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

China
Shire
Takeda Development Center Americas, Inc.

Withdrawn

Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia

COVID-19 Pneumonia
Celgene

Terminated

A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

Discoid Lupus

United States
Merck Sharp & Dohme LLC
United States Department of Defense; BioProtection Systems Corporation

Completed

Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)

Ebola Virus
Sonova AG

Completed

Quality Control of CE-Certified Phonak Hearing Aids - 2016_06

Hearing Loss

Switzerland
Cecile Tremblay
Merck Sharp & Dohme LLC; Dalhousie University; Université de Montréal; Coalition... and other collaborators

Active, not recruiting

African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola

Ebola

Canada
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease (RAISE)

Sickle Cell Disease

United States
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Angioedema

United States, Spain, Netherlands, Hungary, Italy, Canada, Germany, France, Japan, Poland
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United States, Spain, Italy, Greece, United Kingdom, Argentina, Poland, Austria
Charite University, Berlin, Germany
Shire International GmbH

Active, not recruiting

Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS) (LANA-FXII)

Hereditary Autoinflammatory Disease

Germany
Shire
Dyax Corp.

Completed

A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

Hereditary Angioedema (HAE)

United States
United States Department of Agriculture (USDA)
University of Connecticut

Completed

Soy and Isoflavones Effect on Bone

Osteoporosis

United States
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Angioedema

United States, France, Netherlands, Spain, Hungary, Italy, Canada, Poland, Japan, Germany
Shire

Completed

Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

Japan
Shire

Completed

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Hereditary Angioedema (HAE)

United States, United Kingdom, Germany, Canada, Italy, Jordan, Puerto Rico
Takeda
Shire; Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura (TTP)

China, United States, France, Japan, Poland, Germany, Austria, Spain, Italy, Switzerland, United Kingdom
Merck Sharp & Dohme LLC

Terminated

A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

Neoplasm Metastasis

United States, Canada, Israel
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United States, Spain, Poland, Italy, Germany, France, Switzerland, Austria, Japan, United Kingdom
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004)

Renal Cell Carcinoma

United States, Australia, Canada, Chile, Taiwan
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (INTerpath-002)

Non-small Cell Lung Cancer

United States, New Zealand, Australia, Costa Rica, Taiwan, Argentina, France, Chile, Hungary, Spain, Greece, Poland
Merck Sharp & Dohme LLC
Moderna TX

Recruiting

A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

Carcinoma, Squamous Cell | Skin Neoplasms

Australia, Israel
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005)

Bladder Cancer

Canada, Germany, Australia, United States, Poland, Spain, Chile, France
Shire
Takeda Development Center Americas, Inc.

No longer available

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

Angioedema | Hereditary Angioedema (HAE)

United States, Canada, Germany, Hungary, Spain
Ikena Oncology

Recruiting

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Solid Tumor | Solid Tumors, Adult | Malignant Pleural Mesothelioma (MPM) | Epithelioid Hemangioendothelioma (EHE) | NF2 Deficient Mesothelioma | Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes | NF2 Deficiency | YAP1 or TAZ Gene Fusions

United States, United Kingdom
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Advanced Solid Tumors

United States, United Kingdom
National Institute of Allergy and Infectious Diseases...
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Active, not recruiting

Partnership for Research on Ebola VACcinations (PREVAC)

Ebola Virus Disease

Guinea, Liberia, Mali, Sierra Leone
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Melanoma

Spain, Italy, Poland, Brazil, Australia, Chile, Canada, Portugal, Turkey, Germany, Greece, Israel, Sweden, New Zealand, United States, Belgium, France, Taiwan, United Kingdom, Switzerland, South Africa, Denmark, Argentina
Merck Sharp & Dohme LLC

Terminated

A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)

Neoplasm Metastasis

United States, Canada, France, Germany, Hungary, Israel, Italy, Japan, Norway, Peru, Poland, Portugal, Spain, Taiwan
Merck Sharp & Dohme LLC

Terminated

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Advanced/Metastatic Melanoma

United States, Australia, Chile, France, Germany, Israel, Italy, Korea, Republic of, Norway, South Africa, Spain
Cornell University

Enrolling by invitation

Maternal Choline Supplementation and Offspring Cognition in Adolescence (CholTeens)

Executive Dysfunction | Emotional Regulation | Cognitive Deficit in Attention

United States
Centre de Recherche Médicale de Lambaréné
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon (EBOLAPED)

Ebola Virus Disease

Gabon

Search clinical trials for: V930

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations